Literature DB >> 33409973

Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis.

Saurabh Chandan1, Babu P Mohan2, Shahab R Khan3, Antonio Facciorusso4, Daryl Ramai5, Lena L Kassab6, Neil Bhogal7, Ravishankar Asokkumar8, Gortrand Lopez-Nava8, Stephanie McDonough2, Douglas G Adler9.   

Abstract

Intragastric balloon (IGB) therapy has shown efficacy in weight loss but its role in NAFLD remains unknown. We conducted a systematic review and meta-analysis to evaluate the efficacy of IGB in NAFLD. Meta-analysis was performed to estimate the pooled proportion of patients with improvement in steatosis as determined by imaging and histology following IGB placement. Nine studies were included in our analysis. Four hundred forty-two IGBs were placed. Improvement in steatosis was seen in 79.2% of patients and NAS in 83.5% of patients, and HOMA-IR score improved in 64.5% of patients. A reduction in liver volume by CT scan was noticed in 93.9% of patients undergoing IGB placement. IGB is an effective and safe short-term therapeutic modality for patients with NAFLD.

Entities:  

Keywords:  Bariatric endoscopy; Fatty liver; Intragastric balloon; NAFLD; Weight loss

Mesh：

Year:  2021        PMID： 33409973     DOI： 10.1007/s11695-020-05084-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN： 0960-8923            Impact factor:   4.129


  49 in total

Review 1.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

2.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

7.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Authors:  Anna Ludovica Fracanzani; Luca Valenti; Elisabetta Bugianesi; Marco Andreoletti; Agostino Colli; Ester Vanni; Cristina Bertelli; Erika Fatta; Daniela Bignamini; Giulio Marchesini; Silvia Fargion
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

Review 9.  Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).

Authors:  Menso J Westerouen Van Meeteren; Joost P H Drenth; Eric T T L Tjwa
Journal:  Expert Opin Investig Drugs       Date:  2019-09-25       Impact factor: 6.206

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682
View more
  2 in total

Review 1.  European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.

Authors:  Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda
Journal:  United European Gastroenterol J       Date:  2022-08-12       Impact factor: 6.866

2.  Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Mengting Ren; Xinxin Zhou; Yunyun Zhang; Feifei Mo; Jinpu Yang; Mosang Yu; Feng Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.